Article

Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE Trial

2022-10-11

Abstract excerpt

Background: The SAVE-MORE trial demo that anakinra treatment in COVID-19 pneumonia with plasma suPAR (soluble urokinase plasminogen activator) 6ng/ml or more was associated with 0.36 odds for worse outcome compared to placebo as expressed by the WHO-CPS (Clinical Progression Scale) at day 28. Subgroup analyses and long-term outcomes are reported.<br><br>Methods: SAVE-MORE was a prospective, double-blind randomized...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7ed778ad-6800-587f-88c7-1396acdd7799
DOI: 10.2139/ssrn.4244749

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialDOI 10.2139/ssrn.4244749Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Azvudine Reduce the In-Hospital Mortality of Patients with COVID-19 PneumoniaSemantic proximity Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19Semantic proximity Read

On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity Read

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)Semantic proximity Read

A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1Semantic proximity Read

Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read

Clinical characteristics study of elderly patients aged 75 or older with COVID-19 pneumonia in ChinaSemantic proximity Read